Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
ESPR Esperion Therapeutics, Inc. daily Stock Chart
ESPR [NASD]
Esperion Therapeutics, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-3.69 Insider Own0.60% Shs Outstand28.62M Perf Week-2.51%
Market Cap1.96B Forward P/E- EPS next Y-5.80 Insider Trans109.19% Shs Float26.51M Perf Month21.58%
Income-95.30M PEG- EPS next Q-2.59 Inst Own- Short Float18.45% Perf Quarter53.60%
Sales147.40M P/S13.27 EPS this Y-8.10% Inst Trans2.84% Short Ratio8.35 Perf Half Y79.87%
Book/sh2.52 P/B27.12 EPS next Y-50.30% ROA-40.40% Target Price86.42 Perf Year55.77%
Cash/sh8.52 P/C8.02 EPS next 5Y28.30% ROE-84.30% 52W Range33.13 - 76.98 Perf YTD14.62%
Dividend- P/FCF- EPS past 5Y-17.90% ROI- 52W High-15.24% Beta2.09
Dividend %- Quick Ratio4.40 Sales past 5Y- Gross Margin- 52W Low96.95% ATR3.78
Employees76 Current Ratio4.40 Sales Q/Q- Oper. Margin- RSI (14)55.99 Volatility6.36% 6.43%
OptionableYes Debt/Eq0.00 EPS Q/Q-35.10% Profit Margin-64.60% Rel Volume1.37 Prev Close68.35
ShortableYes LT Debt/Eq0.00 EarningsFeb 27 BMO Payout- Avg Volume585.75K Price65.25
Recom1.80 SMA206.84% SMA5012.07% SMA20039.55% Volume572,691 Change-4.54%
Feb-14-20Downgrade Citigroup Buy → Neutral $82
Sep-16-19Upgrade Goldman Sell → Neutral $55 → $45
May-29-19Downgrade Goldman Neutral → Sell
May-06-19Upgrade BofA/Merrill Underperform → Neutral
Apr-26-19Upgrade Goldman Sell → Neutral $50
Mar-13-19Upgrade JP Morgan Underweight → Neutral $38 → $47
Jan-07-19Reiterated Needham Strong Buy $94 → $114
Dec-13-18Initiated Goldman Sell $45
Oct-29-18Upgrade Northland Capital Market Perform → Outperform
Oct-16-18Initiated BTIG Research Buy $82
Aug-17-18Upgrade Citigroup Neutral → Buy
Jul-11-18Downgrade Northland Capital Outperform → Market Perform
May-03-18Downgrade JP Morgan Neutral → Underweight $41
May-02-18Downgrade BofA/Merrill Buy → Underperform
Mar-27-18Reiterated Chardan Capital Markets Neutral $75 → $100
Feb-21-18Reiterated Needham Strong Buy $81 → $94
Jan-22-18Downgrade Citigroup Buy → Neutral
Jan-18-18Initiated Credit Suisse Outperform $103
Jan-17-18Reiterated UBS Buy $62 → $88
Jan-05-18Upgrade BofA/Merrill Neutral → Buy
Feb-16-20 03:03PM  The Week Ahead In Biotech: Baudax Bio, Merck, Esperion Await FDA Decisions Benzinga
Feb-03-20 01:30PM  Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates Benzinga +5.68%
Jan-31-20 07:02AM  Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for the Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia GlobeNewswire
07:01AM  Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for Bempedoic Acid for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia GlobeNewswire
Jan-27-20 12:20PM  One Thing To Remember About The Esperion Therapeutics, Inc. (NASDAQ:ESPR) Share Price Simply Wall St.
Jan-07-20 07:30AM  Esperion to Present at the 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-03-20 04:15PM  Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Dec-12-19 11:59AM  Did Hedge Funds Drop The Ball On Esperion Therapeutics (ESPR) ? Insider Monkey
Dec-06-19 11:31AM  Esperion Therapeutics (ESPR) Up 25.1% Since Last Earnings Report: Can It Continue? Zacks +6.30%
Nov-28-19 07:09AM  Esperion's Promising Drugs Under Review, Funds a Concern Zacks
Nov-22-19 06:30PM  Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire +5.25%
Nov-19-19 09:13AM  Esperion Therapeutics (ESPR) Catches Eye: Stock Jumps 10% Zacks
Nov-17-19 03:05PM  Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific Sessions GlobeNewswire
Nov-12-19 11:05AM  Esperion Announces Publication in the Journal of the American Medical Association of Bempedoic Acid Phase 3 Study 2 Results GlobeNewswire
Nov-10-19 07:56AM  President Timothy Mayleben Just Bought Shares In Esperion Therapeutics, Inc. (NASDAQ:ESPR) Simply Wall St.
Nov-09-19 09:26AM  Is Esperion Therapeutics's (NASDAQ:ESPR) Share Price Gain Of 215% Well Earned? Simply Wall St.
Nov-07-19 11:04AM  Esperion (ESPR) Reports Wider-Than-Expected Loss in Q3 Zacks
07:30AM  Esperion to Participate in Upcoming Investor Conferences GlobeNewswire
Nov-06-19 08:45AM  Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates Zacks -8.65%
07:30AM  Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter Financial Results GlobeNewswire
Nov-04-19 07:30AM  Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of Bempedoic Acid to be Presented at the American Heart Association 2019 Scientific Sessions GlobeNewswire
Oct-29-19 07:30AM  Esperion to Report Third Quarter 2019 Financial Results November 6, 2019 GlobeNewswire
Oct-28-19 05:15PM  Should You Buy Esperion Therapeutics, Inc. (ESPR)? Insider Monkey
Oct-25-19 10:00AM  Bempedoic Acid Included in Top 10 Medical Innovations for 2020 List GlobeNewswire
Oct-04-19 08:34AM  Here's Why We're Not At All Concerned With Esperion Therapeutics's (NASDAQ:ESPR) Cash Burn Situation Simply Wall St.
Sep-09-19 10:57AM  7 Micro-Cap and Small-Cap Stocks That Insiders Are Buying InvestorPlace
Sep-07-19 09:30AM  Esperion Therapeutics (ESPR) Down 10.8% Since Last Earnings Report: Can It Rebound? Zacks
Sep-06-19 06:15PM  Esperion Therapeutics Inc (ESPR) President & CEO Timothy M Mayleben Bought $259,125 of Shares GuruFocus.com
Aug-30-19 04:15PM  Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
10:26AM  Esperion's Bempedoic Acid Succeeds in Phase II Diabetes Study Zacks
Aug-29-19 07:30AM  Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Tablet in Patients with Hypercholesterolemia and Type 2 Diabetes GlobeNewswire
Aug-26-19 11:05AM  Esperion's Drugs in Review Hold Potential, Funds a Concern Zacks
Aug-20-19 11:15AM  Does Market Volatility Impact Esperion Therapeutics, Inc.'s (NASDAQ:ESPR) Share Price? Simply Wall St.
Aug-09-19 08:06AM  Esperion (ESPR) Q2 Loss Wider Than Expected, Revenues Beat Zacks
Aug-08-19 09:15AM  Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:30AM  Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter Financial Results GlobeNewswire
Aug-06-19 04:15PM  Esperion to Present at the BTIG Biotechnology Conference GlobeNewswire
Aug-02-19 07:15PM  Esperion Therapeutics Inc (ESPR) President & CEO Timothy M Mayleben Bought $197,800 of Shares GuruFocus.com
Jul-31-19 01:48PM  Steven Cohen Charges Into Chiasma GuruFocus.com
Jul-30-19 04:15PM  Esperion to Report Second Quarter 2019 Financial Results August 8, 2019 GlobeNewswire
03:16PM  A Firm's First Profit Can Mean Big Returns for Investors Zacks
Jul-29-19 08:08AM  3 Biotech Stocks Corporate Insiders are Buying TipRanks
Jul-07-19 07:10PM  Weekly CEO Buys Highlight GuruFocus.com
Jul-05-19 12:25PM  Is Esperion Therapeutics, Inc. (ESPR) A Good Stock To Buy? Insider Monkey
Jun-26-19 04:10PM  Esperion and Oberland Capital Announce $200 Million Funding Agreement GlobeNewswire
Jun-19-19 10:40AM  Have Insiders Been Buying Esperion Therapeutics, Inc. (NASDAQ:ESPR) Shares This Year? Simply Wall St.
Jun-07-19 09:30AM  Esperion Therapeutics (ESPR) Down 5.6% Since Last Earnings Report: Can It Rebound? Zacks
May-30-19 04:15PM  Esperion Announces the Appointment of Tracy M. Woody to Board of Directors GlobeNewswire
May-29-19 04:23PM  Biotech Stocks Clobbered As Two Slammed With Sell Ratings Investor's Business Daily
May-28-19 07:00AM  Esperion to Participate in Upcoming Investor Conferences GlobeNewswire
May-27-19 06:00AM  Esperion Aims for the First Approved Non-Statin Cholesterol Reducer MoneyShow
May-10-19 08:00AM  Esperion to Participate in Upcoming Investor Conferences GlobeNewswire
May-09-19 06:00AM  Esperion Gets a Go-Ahead from the FDA MoneyShow
May-08-19 08:35AM  Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Surpass Estimates Zacks
07:25AM  Esperion Therapeutics: 1Q Earnings Snapshot Associated Press
07:00AM  Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports First Quarter Financial Results GlobeNewswire
May-07-19 05:30AM  Esperion to Host Analyst and Investor Day Event on May 30 GlobeNewswire
May-06-19 04:15PM  A Single Rival Caused 2 Biopharma Stocks To Slip Here's Why Investor's Business Daily +11.56%
01:30PM  Here's Why Esperion Therapeutics Shares Rocketed 11.5% Higher Today Motley Fool
10:33AM  Small-Cap Biotech Esperion Surges On FDA Acceptance Of Cholesterol Drug Applications Benzinga
May-05-19 05:00PM  Esperion Announces U.S. FDA Acceptance of New Drug Applications (NDAs) for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet for Filing and Regulatory Review GlobeNewswire
May-02-19 02:41PM  Heres What Hedge Funds Think About Esperion Therapeutics, Inc. (ESPR) Insider Monkey
Apr-24-19 02:12PM  Moore Kuehn Encourages Esperion Therapeutics, Inc. Investors to Contact Law Firm for Possible Claims Against Officers and Directors PR Newswire
Apr-07-19 10:45PM  Weekly CEO Buys Highlight GuruFocus.com
Apr-02-19 04:30PM  Esperion to Present at the Needham & Company 18th Annual Healthcare Conference GlobeNewswire +8.04%
Apr-01-19 07:15PM  Esperion Therapeutics Inc (ESPR) President & CEO Timothy M Mayleben Bought $200,000 of Shares GuruFocus.com
04:15PM  Esperion Announces Publication in The Journal of the American Heart Association of Bempedoic Acid Study 3 Results GlobeNewswire
Mar-30-19 09:30AM  Esperion Therapeutics (ESPR) Down 12.9% Since Last Earnings Report: Can It Rebound? Zacks
Mar-21-19 07:15PM  Esperion Therapeutics Inc (ESPR) President & CEO Timothy M Mayleben Bought $217,400 of Shares GuruFocus.com
Mar-18-19 09:20AM  Esperion Announces Late-Breaking Presentation of Final Results of Bempedoic Acid Pivotal Phase 3 Study 2 at the American College of Cardiology 2019 Scientific Sessions GlobeNewswire
Mar-14-19 09:15PM  Esperion Therapeutics Inc (ESPR) President & CEO Timothy M Mayleben Bought $243,650 of Shares GuruFocus.com -8.47%
Mar-13-19 05:05PM  Esperion Announces Publication of Bempedoic Acid Study 1 Results in The New England Journal of Medicine GlobeNewswire +7.55%
Mar-12-19 07:19AM  Did You Miss Esperion Therapeuticss (NASDAQ:ESPR) Impressive 225% Share Price Gain? Simply Wall St.
Mar-05-19 08:25AM  New Research Coverage Highlights Advance Auto Parts, AxoGen, Encana, Federal Signal, Nelnet, and Esperion Therapeutics Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
Mar-04-19 04:30PM  Esperion to Participate in Upcoming Investor Conferences GlobeNewswire
08:00AM  Esperion Announces Presentation of Bempedoic Acid Pivotal Phase 3 Study 2 Results in a Late-Breaking Clinical Trial Session at the American College of Cardiology 2019 Scientific Sessions GlobeNewswire
Mar-01-19 09:39AM  Esperion (ESPR) Reports Wider-Than-Expected Loss in Q4 Zacks
Feb-28-19 04:30PM  Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
07:00AM  Esperion Announces Submissions of Two NDAs and Official Completion of Two MAA Validations for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet GlobeNewswire
Feb-22-19 05:30PM  Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire +5.39%
Jan-29-19 08:45AM  Update in Lawsuit for Investors in NASDAQ: ESPR shares against Esperion Therapeutics, Inc. announced by Shareholders Foundation GlobeNewswire
Jan-11-19 09:16AM  For Esperion Therapeutics, 2019 Could Be a Big Year Motley Fool
Jan-07-19 07:15AM  Update: Lawsuit for Investors in shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) announced by Shareholders Foundation ACCESSWIRE
02:00AM  Daiichi Sankyo Europe Enters into European Licensing Agreement with Esperion for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet PR Newswire
Jan-06-19 10:00AM  All the Pre-JPM News Healthcare Investors Need to Know Motley Fool
Jan-04-19 04:34PM  Why Arcus Biosciences, Eldorado Gold, and Esperion Therapeutics Slumped Today Motley Fool -6.12%
07:20AM  Esperion to receive $300 million in upfront payments in deal with Daiichi Sankyo MarketWatch
07:00AM  Esperion Announces Agreement with Daiichi Sankyo Europe (DSE) to Commercialize Bempedoic Acid in Europe GlobeNewswire
Jan-02-19 04:15PM  Esperion to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-19-18 10:28PM  Is Esperion Therapeutics, Inc. (ESPR) A Good Stock To Buy? Insider Monkey
Nov-14-18 08:52AM  Do Options Traders Know Something About Esperion (ESPR) Stock We Don't? Zacks -7.42%
Nov-10-18 08:15AM  Esperion Announces Late-Breaking Oral Presentation of Final Study 3 Results (1002-046) of Bempedoic Acid at the American Heart Association Scientific Sessions 2018 GlobeNewswire
Nov-09-18 07:50AM  Report: Exploring Fundamental Drivers Behind American Vanguard, Pioneer Natural Resources, American States Water, Groupon, Esperion Therapeutics, and Paylocity Holding New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire -6.79%
Nov-08-18 08:44AM  What's Next for Esperion Therapeutics' Cholesterol-Lowering Drug Motley Fool
08:00AM  Esperion to Participate in Upcoming Investor Conferences GlobeNewswire
06:00AM  3 Biotech Stocks Poised for Big Rebounds Investopedia
Nov-01-18 04:05PM  Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2018 Financial Results GlobeNewswire +9.93%
Oct-31-18 02:27PM  Esperion CEO on safety of new cholesterol drug CNBC Videos +6.44%
Oct-29-18 07:43AM  Esperion stock surges 15% on late-stage results for cholesterol drug MarketWatch
Oct-28-18 05:10PM  Esperion Announces Completion of Phase 3 LDL-C Lowering Development Program of Bempedoic Acid and Positive Cumulative Results GlobeNewswire
Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination tablet, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIOTECH TARGET N V10% OwnerJan 23Buy52.1220,0001,042,3983,747,964Jan 27 12:51 PM
MAYLEBEN TIMOTHY MPresident & CEONov 06Buy36.985,000184,90083,663Nov 08 04:14 PM
BIOTECH TARGET N V10% OwnerNov 06Buy37.3075,0002,797,5603,727,964Nov 08 02:54 PM
MAYLEBEN TIMOTHY MPresident & CEOSep 06Buy35.252,50088,12578,663Sep 06 04:22 PM
MAYLEBEN TIMOTHY MPresident & CEOSep 04Buy34.205,000170,98276,163Sep 06 04:22 PM
BIOTECH TARGET N V10% OwnerSep 04Buy33.7880,0002,702,2083,652,964Sep 06 04:09 PM
MAYLEBEN TIMOTHY MPresident & CEOAug 01Buy39.565,000197,80071,163Aug 02 04:06 PM
BIOTECH TARGET N V10% OwnerJul 23Buy42.6550,0002,132,5653,572,964Jul 25 12:42 PM
MAYLEBEN TIMOTHY MPresident & CEOJun 28Buy46.005,000230,00066,163Jul 01 04:57 PM
MAYLEBEN TIMOTHY MPresident & CEOMar 29Buy40.005,000200,00061,163Apr 01 04:41 PM
MAYLEBEN TIMOTHY MPresident & CEOMar 20Buy43.485,000217,40056,163Mar 21 05:01 PM
VITULLO NICOLEDirectorMar 19Sale44.7315,329685,5960Mar 21 09:02 AM
MAYLEBEN TIMOTHY MPresident & CEOMar 14Buy48.735,000243,65051,163Mar 14 04:57 PM
BIOTECH TARGET N V10% OwnerMar 14Buy49.8950,0002,494,3553,522,964Mar 15 07:50 PM
NEWTON ROGER SDirectorMar 12Sale50.0625,0001,251,500548,726Mar 14 04:57 PM
open in yahoo | open in reuters | open in google